{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2F+Refractory+T-cell+Malignancies&page=17",
    "query": {
      "condition": "Relapsed/ Refractory T-cell Malignancies",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 845,
    "total_pages": 85,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2F+Refractory+T-cell+Malignancies&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2F+Refractory+T-cell+Malignancies&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T17:05:06.562Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01658319",
      "title": "Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Nasal Type Extranodal NK/T-cell Lymphoma",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Hepatosplenic T-cell Lymphoma",
        "Intraocular Lymphoma",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Multiple Myeloma",
        "Relapsing Chronic Myelogenous Leukemia",
        "Small Intestine Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Stage III Chronic Lymphocytic Leukemia",
        "Testicular Lymphoma",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methoxyamine",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "western blotting",
          "type": "GENETIC"
        },
        {
          "name": "mass spectrometry",
          "type": "OTHER"
        },
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "GENETIC"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2011-05",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2015-08-13",
      "last_synced_at": "2026-10-15T17:05:06.562Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01658319"
    },
    {
      "nct_id": "NCT05908396",
      "title": "Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "IGM-2644",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IGM Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2023-08-29",
      "completion_date": "2024-02-16",
      "has_results": false,
      "last_update_posted_date": "2024-08-01",
      "last_synced_at": "2026-10-15T17:05:06.562Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Denver, Colorado • New York, New York + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05908396"
    },
    {
      "nct_id": "NCT04502446",
      "title": "A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "T Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "CTX130",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CRISPR Therapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2020-07-31",
      "completion_date": "2024-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-01-08",
      "last_synced_at": "2026-10-15T17:05:06.562Z",
      "location_count": 8,
      "location_summary": "Duarte, California • Stanford, California • New Haven, Connecticut + 5 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04502446"
    },
    {
      "nct_id": "NCT04771572",
      "title": "Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Hodgkin Lymphoma",
        "Richter Transformation",
        "Multiple Myeloma",
        "T-cell-prolymphocytic Leukemia",
        "Acute Myeloid Leukemia",
        "Acute Lymphocytic Leukemia",
        "Myeodysplastic Syndrome",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Myelofibrosis",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma",
        "Chronic Myelomonocytic Leukemia-2",
        "Myelodysplastic Neoplasm in Blast Phase"
      ],
      "interventions": [
        {
          "name": "LP-118",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Newave Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2022-05-08",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-15T17:05:06.562Z",
      "location_count": 8,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Chapel Hill, North Carolina + 4 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04771572"
    },
    {
      "nct_id": "NCT04244656",
      "title": "A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "CTX120",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CRISPR Therapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2020-01-22",
      "completion_date": "2024-01-04",
      "has_results": false,
      "last_update_posted_date": "2025-01-08",
      "last_synced_at": "2026-10-15T17:05:06.562Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Portland, Oregon • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04244656"
    },
    {
      "nct_id": "NCT07566585",
      "title": "Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AML - Acute Myeloid Leukemia",
        "AML With Mutated NPM1",
        "AML, Adult Recurrent"
      ],
      "interventions": [
        {
          "name": "SOC+BSB-2002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BlueSphere Bio, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2026-04-21",
      "completion_date": "2026-09-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-15T17:05:06.562Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07566585"
    },
    {
      "nct_id": "NCT05172596",
      "title": "PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "PHE885",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 146,
      "start_date": "2022-03-03",
      "completion_date": "2025-05-21",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-10-15T17:05:06.562Z",
      "location_count": 6,
      "location_summary": "Palo Alto, California • Atlanta, Georgia • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05172596"
    },
    {
      "nct_id": "NCT03843294",
      "title": "Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hodgkin Lymphoma",
        "Diffuse Large B Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "TAA-T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Catherine Bollard",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "12 Years to 80 Years"
      },
      "enrollment_count": 18,
      "start_date": "2019-06-24",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-10-15T17:05:06.562Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03843294"
    },
    {
      "nct_id": "NCT06559189",
      "title": "CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-cell Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "CD19x22 CAR T",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "3 Months to 30 Years"
      },
      "enrollment_count": 53,
      "start_date": "2024-09-27",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-28",
      "last_synced_at": "2026-10-15T17:05:06.562Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06559189"
    },
    {
      "nct_id": "NCT04176380",
      "title": "RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsed, Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "RAPA-201 Autologous T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Rapa Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2020-12-02",
      "completion_date": "2023-06-06",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-10-15T17:05:06.562Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04176380"
    }
  ]
}